Macrophage flipping from foe to friend: A matter of interest in breast carcinoma heterogeneity driving drug resistance.

Macrophage flipping from foe to friend: A matter of interest in breast carcinoma heterogeneity driving drug resistance. Curr Cancer Drug Targets. 2018 Jun 27;: Authors: Tandon I, Sharma NK Abstract Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create interface with outside environment that lead to the unique identity of a specific cancer type. Among various contributors to tumor heterogeneity, cellular heterogeneity immensely plays a role in drug resistance and relapse of cancer. Within cellular heterogeneity of tumor, tumor-associated macrophages (TAMs) are pro-tumor type of immune cells that promote growth, metastasis and drug resistance in breast carcinoma and other cancer types. Revealing the molecular aspects of TAMs can provide a breakthrough to remove therapeutics blockade to existing drugs and these understanding in future pave the way a new class of cancer immunotherapeutic. This review addresses current understanding on the role of TAMs in breast carcinoma hallmarks and clarifies the current scenario on pre-clinical drugs directed to tame pro-cancer TAMs. PMID: 29952260 [PubMed - as supplied by publisher]
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Tags: Curr Cancer Drug Targets Source Type: research